Methods of treating respiratory disorders

Patent metadata

Field	Value
Publication number	US-10537557-B2
Application number	US-201715418126-A
Country	US
Kind code	B2
Filing date	Jan 27, 2017
Priority date	Jan 27, 2016
Publication date	Jan 21, 2020
Grant date	Jan 21, 2020

Abstract

A method of treating a hyperoxia induced disease or disorder associated with GSNO deficiency in a subject in need thereof includes administering to the subject a therapeutically effective amount of GSNO or a GSNO promoting agent.

First claim

Having described the invention, we claim:

1. A method of treating bronchopulmonary dysplasia (BPD) in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a pyrrole inhibitor of GSNO reductase, wherein the subject is a prematurely born neonatal human subject exposed to supplemental oxygen treatment, and wherein the pyrrole inhibitor of GSNO reductase comprising a compound having the formula:

and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the pyrrole inhibitor of GSNO reductase is administered to the subject via intraperitoneal administration.

3. The method of claim 1 , wherein the therapeutically effective amount of the pyrrole inhibitor of GSNO reductase is an amount effective to increase the level of GSNO in the subject's lung tissue.

Assignees

• Univ Case Western Reserve

Inventors

• Raffay Thomas M
• Gaston Benjamin M

Classifications

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/0078

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title

• A61K31/4178 Primary

  not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin · CPC title